Literature DB >> 8972696

Complement activation in human serum by liposome-encapsulated hemoglobin: the role of natural anti-phospholipid antibodies.

J Szebeni1, N M Wassef, A S Rudolph, C R Alving.   

Abstract

In exploring the occurrence and mechanism of liposome-encapsulated hemoglobin (LEH)-induced complement (C) activation, we found that normal human serum contained low titers of IgG and IgM class natural antibodies with reactivity against LEH, and that the amount of vesicle-bound IgM significantly correlated with LEH-induced C consumption. IgM binding to LEH was inhibited by phosphocholine and ATP, but not by choline chloride. These data suggest that naturally occurring antibodies play a key role in LEH-induced C activation, and that a major portion of these antibodies are directed against the phosphate moiety on the phospholipid headgroups of liposome bilayers.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8972696     DOI: 10.1016/s0005-2736(96)00201-5

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  4 in total

Review 1.  Immunological risk of injectable drug delivery systems.

Authors:  Wim Jiskoot; Rianne M F van Schie; Myrra G Carstens; Huub Schellekens
Journal:  Pharm Res       Date:  2009-02-27       Impact factor: 4.200

2.  Complement activation by PEGylated single-walled carbon nanotubes is independent of C1q and alternative pathway turnover.

Authors:  Islam Hamad; A Christy Hunter; Kenneth J Rutt; Zhuang Liu; Hongjie Dai; S Moein Moghimi
Journal:  Mol Immunol       Date:  2008-07-03       Impact factor: 4.407

3.  Understanding the Role of Anti-PEG Antibodies in the Complement Activation by Doxil in Vitro.

Authors:  Barry W Neun; Yechezkel Barenholz; Janos Szebeni; Marina A Dobrovolskaia
Journal:  Molecules       Date:  2018-07-12       Impact factor: 4.411

Review 4.  Roadmap and strategy for overcoming infusion reactions to nanomedicines.

Authors:  Janos Szebeni; Dmitri Simberg; África González-Fernández; Yechezkel Barenholz; Marina A Dobrovolskaia
Journal:  Nat Nanotechnol       Date:  2018-10-22       Impact factor: 39.213

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.